Here’s a bold statement: What if stopping blood thinners after a successful atrial fibrillation (AF) ablation could be safe for certain patients? This idea is shaking up the medical community, and the OCEAN trial is at the heart of the debate. But here’s where it gets controversial—while the trial suggests low-risk patients might not need oral anticoagulants (DOACs) post-ablation, experts are quick to warn that this doesn’t apply to everyone. So, who exactly qualifies, and what does this mean for the future of AF treatment?
At the American Heart Association 2025 Scientific Sessions, researchers revealed that patients treated with aspirin after successful AF ablation faced no greater risk of stroke or other adverse outcomes compared to those on the direct oral anticoagulant rivaroxaban (Xarelto). Over 36 months, rates of stroke, systemic embolism, and small cerebral infarctions detected by MRI were strikingly similar in both groups. And this is the part most people miss—lead investigator Dr. Atul Verma suggests that patients with a CHA2DS2-VASc score of 1, 2, or even 3 might safely discontinue DOACs after ablation. However, he cautions that the trial lacked patients with recent strokes, so those with a CHA2DS2-VASc score of 2 due to a recent stroke may not fit this profile.
The ALONE-AF study echoes these findings, showing better clinical outcomes for patients who stopped oral anticoagulation after successful ablation. Yet, current U.S. and European guidelines still recommend long-term anticoagulation based on stroke risk, leaving many physicians in a quandary. Here’s the kicker—despite growing evidence, deciding whether to stop DOACs remains a complex, patient-specific decision that requires careful conversation.
Electrophysiologist Dr. Oussama Wazni agrees that for low-risk patients maintaining normal sinus rhythm, stopping medication is a reasonable option. However, he emphasizes the difficulty of these decisions in real-world practice. “We’ve all seen patients with a CHA2DS2-VASc score of 0 who still had a stroke months later,” he notes. This highlights the need for open, data-driven discussions with patients.
Dr. Christine Albert adds that while anticoagulation is typically continued long-term due to concerns about silent AF and stroke risk, the OCEAN trial provides valuable risk-benefit data. For patients a year out from successful ablation with low-to-moderate stroke risk, discontinuing DOACs might be an option.
The OCEAN trial, published in the New England Journal of Medicine, included 1,284 patients (mean age 66, 71.5% male) with a CHA2DS2-VASc score of 1 or more. Patients were randomized to either daily aspirin (70-120 mg) or a modified 15-mg dose of rivaroxaban, starting a median of 16.4 months after ablation. The trial was halted in 2022 due to the high likelihood of no difference in outcomes between the groups.
At three years, the primary composite outcome (stroke, systemic embolism, or new covert embolic stroke) occurred in 0.8% of rivaroxaban patients and 1.4% of aspirin patients—a nonsignificant difference. Stroke rates alone were 0.8% in the rivaroxaban group and 1.1% in the aspirin group. Fatal or major bleeding, the primary safety endpoint, was slightly higher in the rivaroxaban group (1.6% vs. 0.6% in aspirin patients).
Here’s the controversial part—the trial used aspirin as a comparator to rivaroxaban, but recent evidence suggests aspirin may not reduce stroke risk in low-risk patients, making it more like a placebo. This raises questions about the trial’s design and whether aspirin was the best choice for comparison.
Dr. Michael Ghannam points out that while ablation reduces AF burden and improves quality of life, its impact on stroke risk remains unclear. He cautions against broadly discontinuing anticoagulants, especially in high-risk patients, but acknowledges the trial’s significance in addressing a growing clinical need.
For physicians hesitant to stop DOACs, Dr. Wazni suggests apixaban (Eliquis) as an alternative due to its lower bleeding risk. He also reminds us that while bleeding is often reversible, stroke can be life-altering. The OPTION study further complicates the picture, suggesting left atrial appendage occlusion (LAAO) as a potential alternative to DOACs, with similar outcomes and less bleeding.
So, what do you think? Is stopping DOACs after successful AF ablation a game-changer for low-risk patients, or is it too risky? Share your thoughts in the comments—let’s spark a discussion!
